TuHURA Biosciences, Inc. (HURA)
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
- Symbol
- HURA
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $131.19M
- 52 week range
- 0.41 - 3.43
Valuation
- Share price
- $2.05 (close of 2026-09-23)
- P/E (TTM)
- -3.81x
- Price to book
- 7.09x
- Price to free cash flow
- -4.39x
- Enterprise value
- $139.37M
- Book value per share
- $0.29
Price performance
| Period | Change |
|---|
| 1 day | -5.96% |
| 5 days | +0.99% |
| 1 month | +2.50% |
| 3 months | -22.35% |
| 6 months | +3.54% |
| Year to date | +169.74% |
| 1 year | -18.00% |
| 3 years | -98.66% |
| 5 years | -99.90% |
| 10 years | -100.00% |
| All time | -99.99% |
Profitability and growth
- Return on equity
- -143.57%
- Return on assets
- -109.87%
- Revenue growth
- 0.00%
- Net income growth
- -38.60%
- Free cash flow growth
- -87.37%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -22.79%
- Current ratio
- 0.18x
- Net debt to EBITDA
- -0.28x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- EBITDA
- $-29.35M
- Net income
- $-30.05M
- Earnings per share
- $-0.63
- Research and development
- $20.53M
- Interest expense
- $625.28K
- Shares outstanding
- 47.93M
Income statement by year
| Period end | Net income | EPS |
|---|
| 2025-12-31 | $-30.05M | $-0.63 |
| 2024-12-31 | $-21.68M | $-1.21 |
| 2024-06-30 | $-8.32M | $-11.20 |
| 2023-12-31 | $-29.32M | $-2.47 |
| 2023-06-30 | $-14.65M | $-324.45 |
| 2022-06-30 | $-22.66M | $-903.00 |
| 2021-06-30 | $-38.30M | $-2800.00 |
| 2020-06-30 | $-9.13M | $-1522.50 |
| 2019-06-30 | $-8.05M | $5530.00 |
| 2018-06-30 | $11.14M | $9485.00 |
Margins and returns by year
| Period end | Return on equity |
|---|
| 2025-12-31 | -143.57% |
| 2024-12-31 | -148.57% |
| 2024-06-30 | -221.45% |
| 2023-12-31 | 1880.80% |
| 2023-06-30 | -2003.97% |
| 2022-06-30 | -192.12% |
| 2021-06-30 | -361.95% |
| 2020-06-30 | -3469.96% |
| 2019-06-30 | -408.95% |
| 2018-06-30 | 204.93% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $3.62M | - |
| 2024-12-31 | $12.66M | - |
| 2024-06-30 | $4.91M | - |
| 2023-12-31 | $3.67M | - |
| 2023-06-30 | $1.53M | - |
| 2022-06-30 | $11.78M | - |
| 2021-06-30 | $10.54M | - |
| 2020-06-30 | $2.39M | - |
| 2019-06-30 | $3.72M | - |
| 2018-06-30 | $5.97M | $1.12K |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-27.71M | $6.42M |
| 2024-12-31 | $-14.79M | $1.96M |
| 2024-06-30 | $-7.18M | $607.00K |
| 2023-12-31 | $-12.03M | $478.89K |
| 2023-06-30 | $-11.87M | $1.49M |
| 2022-06-30 | $-20.39M | $2.25M |
| 2021-06-30 | $-18.86M | $5.28M |
| 2020-06-30 | $-7.93M | $495.00K |
| 2019-06-30 | $-6.33M | $426.03K |
| 2018-06-30 | $-9.85M | $495.93K |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-13
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-05-15 | Mar/2026 | - |
| 2026-03-31 | - | - |
| 2025-11-14 | - | - |
| 2025-08-14 | - | - |
| 2025-05-15 | - | - |
| 2024-11-14 | - | - |
| 2024-05-14 | - | - |
| 2024-02-14 | - | - |
Filings and sources
- Company website
- tuhurabio.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades